Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Pulse Biosciences insider transactions on 10/02/2025: The company's Chief Commercial Officer exercised 4,600 stock options at an exercise price of $1.53 and simultaneously sold those 4,600 shares at a weighted average price of $18.53 per share under a Rule 10b5-1 trading plan. After these transactions the reporting person beneficially owned 43,298 shares of common stock and held options to acquire 425,000 shares that expire on 09/23/2032. The Form 4 discloses the 10b5-1 plan adoption date of 05/14/2025 and notes the option grant date of 09/23/2022 with a four-year vesting schedule.
PULSE BIOSCIENCES reported director compensation and a leadership update. The company's board ratified awards granted August 9, 2024, comprising three grants of 200,000 option shares each for a total of 600,000 options. The filing notes 2,753,901 broker non-votes on an item reported as "Against" and includes an entry of "N/A" for related fields. It also states that Mr. LaViolette became President and Chief Executive Officer on January 9, 2025 and remains an ex officio member of the Strategic Advisory Committee.
Pulse Biosciences (PLSE) insider transactions by Kevin Patrick Danahy. The reporting person, the company's Chief Commercial Officer, executed sales and option-related transactions on September 18–19, 2025 under a Rule 10b5-1 trading plan adopted May 14, 2025. On 9/18/2025 he acquired 20,000 shares at $1.53 via option exercise and sold 20,000 shares at a weighted average price of $18.49, leaving 43,298 shares beneficially owned. On 9/19/2025 he exercised 400 shares at $1.53 and sold 400 shares at $18.48; post-transactions his direct beneficial ownership of common stock reported in Table I was 43,298 shares. Options granted 9/23/2022 covering 450,000 shares vest 25% annually; 20,400 options were exercised in these transactions.
Darrin Uecker, Pulse Biosciences (PLSE) Chief Technology Officer and director, reported multiple scheduled trades under a Rule 10b5-1 plan on September 16-17, 2025. He sold 25,000 shares on 9/16 and 20,000 shares on 9/17 at weighted average prices of $16.28 and $16.21 respectively, and purchased shares the same days at an exercise price of $4 under stock options and via market purchases. After the reported transactions his beneficial ownership of common stock is stated as 284,406 shares. Several $4 stock options with various exercisable dates are listed, and the Form notes the trades were executed pursuant to a 10b5-1 plan adopted June 12, 2025.
Form 144 filed for Pulse Biosciences, Inc. (PLSE) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $406,750.00. The filing states the shares were acquired and paid for on 09/18/2025 by exercise of stock options from the issuer, and the approximate date of sale is also listed as 09/18/2025.
The filing lists 67,278,347 shares outstanding, and no other sales by the reporting person in the past three months were reported. The filer represents there is no undisclosed material adverse information and includes the standard signed certification language on trading plans and criminal penalties for false statements.
PULSE BIOSCIENCES insider transactions: Darrin Uecker, Chief Technology Officer and director, executed option exercises and sales under a Rule 10b5-1 plan adopted June 12, 2025. On 09/11/2025, 09/12/2025 and 09/15/2025 he exercised three separate $4 stock option tranches of 25,000 shares each and contemporaneously sold 25,000 shares on each date. The reported weighted-average sale prices ranged by date: $14.41–$15.14 (09/11 weighted $14.78), $13.80–$14.76 (09/12 weighted $14.32), and $15.18–$17.20 (09/15 weighted $15.77). Following the transactions the filings show beneficial ownership positions reported in the Form 4 tables (e.g., 122,872 shares on the non-derivative table after sales). The options became fully vested on September 8, 2019 per the employment agreement.
Pulse Biosciences (PLSE) reported a Form 144 notice showing a proposed sale of 120,000 common shares by means of a broker, with an aggregate market value of $1,772,400 and an approximate sale date of 09/11/2025 on NASDAQ. The filing states the shares were acquired and paid for on 09/11/2025 through the exercise of stock options issued by the company, with payment made in cash. The broker listed is Morgan Stanley Smith Barney LLC. The filer also disclosed two prior open-market sales by the same person in June 2025 totaling 30,000 shares for gross proceeds of $485,700. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Pulse Biosciences announced FDA approval of an Investigational Device Exemption (IDE) to begin a clinical study of its nsPFA Cardiac Surgical System for treating atrial fibrillation (AF). The approved NANOCLAMP AF study is a single-arm, prospective trial designed to show primary effectiveness when used in concomitant cardiac surgery. Up to 20 sites (including two outside the U.S.) are planned to enroll as many as 136 patients. The filing attaches a company press release and reiterates standard forward-looking statement cautions about clinical, regulatory, and technological risks.
Pulse Biosciences announced the enrollment of the first patients in a multicenter, IRB-approved study (PRECISE) evaluating its nsPFA™ Percutaneous Electrode System to treat benign thyroid nodules (BTNs). The filing states the press release dated September 2, 2025, confirms successful initial procedures and that the release is attached as Exhibit 99.1.
The company describes the study as multicenter and IRB-approved, indicating clinical development progress for its proprietary nsPFA technology in a new indication. No financial results, timelines for completion, patient numbers beyond “first patients,” or efficacy/safety data are included in the filing.
Pulse Biosciences announced publication of early clinical data from a first-in-human, single-arm feasibility study of its CellFX nsPFA Percutaneous Electrode System to treat benign thyroid nodules. The study, conducted at a single center in Naples, Italy, used ultrasound-guided ablation for tissue-response assessments and therapeutic intent. Follow-up ultrasounds showed no intranodular fibrosis or scarring. Fully treated nodules had an average 86% reduction in size at one year, with individual reductions up to 93%, and patients experienced symptom relief with reductions greater than 48% as early as two weeks. The company attached the related press release as an exhibit.